BOSTON, June 18, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today launched next generation
risk-based monitoring capabilities, expanding its Perceptive
MyTrials® Data-Driven Monitoring (DDM)
solution. Data-Driven Monitoring now further enables clients
to perform cross-study analysis of quality, risk, and monitoring
work effort by combining analytics, reporting and monitoring
activity into a single cohesive solution. The
enhancements increase a drug developer's ability to demonstrate
appropriate oversight and control of site-related risk, quality,
and performance while simplifying monitoring governance and
execution.
"Centralized monitoring methods are being encouraged by the U.S.
Food and Drug Administration (FDA) and other regulatory
bodies. By combining our DDM and monitoring solution, PAREXEL
clients now have the ability to bridge real-time information gaps
between centralized analysts and in-the-field monitoring teams,
reducing risk, ensuring documentation, and increasing quality,"
said Drew Garty, Senior Director,
Product Management, PAREXEL.
The Perceptive MyTrials Data-Driven Monitoring solution uses a
unique, algorithmic-based approach to clinical monitoring to
determine risk and monitor workload, enabling flexible and scalable
decision-making. Developed by PAREXEL Informatics, it is a key
component of the Perceptive MyTrials platform, an integrated
suite of applications for managing clinical trials.
"Our enhanced data-driven monitoring solution provides users
with greater control over site risk and resourcing, building on
PAREXEL's long-standing track record of developing innovative
technologies to continuously improve clinical processes," said
Xavier Flinois, President of PAREXEL Informatics. "These updates
are the latest example of our continued commitment to make the drug
development process more efficient for our clients."
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 80 locations in 51
countries around the world, and had approximately 17,440 employees
in the third quarter. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, Perceptive MyTrials,
and ClinPhone are trademarks or registered trademarks of PAREXEL
International Corporation or its affiliates. All other
trademarks are the property of their respective owners.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisitions of ClinIntel Limited and Quantum
Solutions India, or enter into new lines of business; the impact on
the Company's business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of foreign currency
exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2015 as filed with the
Securities and Exchange Commission on May 1,
2015, which "Risk Factors" discussion is incorporated by
reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of
any date subsequent to the date of this press release.
Contacts:
Diana Martin,
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-launches-next-generation-data-driven-monitoring-capabilities-within-perceptive-mytrials-solution-300100871.html
SOURCE PAREXEL International Corporation